Quality measurement is here to stay, but a JAMA viewpoint asks if anyone is keeping tabs on the costs of measurement.
In less than 20 years, the need to measure healthcare quality has become obvious. An infrastructure has grown up around the task of creating and validating measures, and deciding which ones CMS or commercial payers will use to connect pay with performance.
Measurement is here to stay, with CMS looking to tie 50% of all payments to value-based care by 2018 and physicians facing new requirements from the Medicare Access and CHIP Reauthorization Act.
But, as 3 authors in JAMA asked last week, is anyone keeping tabs on what measurement costs?
Mark A. Schuster, MD, PhD, and Sarah E. Onorato, BA, both of Boston Children’s Hospital and Harvard Medical School, and David O. Meltzer, MD, PhD, of the University of Chicago, took on this question in their essay, “Measuring the Cost of Quality Measurement: A Missing Link in Quality Strategy,” which observes that when selecting measures, cost is typically not a consideration. And that’s a problem, because the costs—especially data collection—can be considerable and the process time-consuming.
Then, the authors say, there’s the question of who pays. Are costs folded into hospital charges, insurance premiums, or other fees? Will the promise of electronic health records to bring down the cost of extracting data ever live up to the hype?
It’s time to be honest about the cost of measuring quality, the authors say. Bringing transparency and comparing the cost and value of similar measures would let the less useful (and less used) ones be discarded. An expensive measure that has high clinical value could be kept if its value can be demonstrated.
Cost should not be the only factor, they argue. But it has to be part of the equation, because doing so could inspire innovations to bring down the cost of the reporting process. That could also make things less burdensome for doctors and nurses if measurement fits better into the workflow.
The authors are not against measurement. “Measuring quality of care is essential to improving it,” they write. “However, the current, cost-uninformed approach has created a proliferation of measures, many of which are needlessly burdensome for health care organizations.”
If the point of measurement is to reveal what in healthcare has value, they authors say, the measures themselves have to pass muster.
Reference
Schuster MA, Onorato SE, Meltzer DO. Measuring the cost of quality measurement: a missing link in quality strategy [published August 31, 2017]. JAMA. 2017; doi:10.1001/jama.2017.11525
Mental Health Diagnoses, Care Challenges Rise Among US Youth, Report Finds
April 26th 2024While behavioral health care utilization has been rising, the treatment landscape has been falling. New findings show that 20% of youths did not receive any form of treatment within 3 months of their initial behavioral health diagnosis.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Males With Hemophilia A Report Physical, Mental Burdens of Disease Regardless of Severity
April 25th 2024Self-reported data from adult and pediatric males with hemophilia A show that burden of the disease persists regardless of severity, highlighting a need for improved prophylactic treatment.
Read More
Insurance Coverage Limits JAKi Therapy Access for Patients With AA, Especially Non-White Populations
April 25th 2024A survey study showed major barriers to Janus kinase inhibitor (JAKi) therapy for patients with alopecia areata, especially for non-White patients who face higher rates of being uninsured and struggle more to afford the treatment.
Read More